iBio Inc
Research iBio Inc (IBIO) on Bullrun: market cap USD 73.03M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIBIO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 73.03M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 7.73M
- Free cash flow-USD 6.10M
Valuation Snapshot
latest market cap is USD 73.03M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 400.00K | -USD 18.38M | -USD 15.32M | n/a | -1.75 | USD 8.58M | USD 2.45M | USD 14.88M |
| FY2024 | USD 225.00K | -USD 24.91M | -USD 18.76M | n/a | -6.5 | USD 14.21M | USD 4.00M | USD 21.32M |
| FY2023 | USD 0 | -USD 65.01M | -USD 36.17M | n/a | -106.19 | USD 4.30M | USD 16.47M | USD 15.38M |
| FY2022 | USD 1.88M | -USD 50.30M | -USD 44.81M | 115.0% | -5.78 | USD 22.68M | USD 27.79M | USD 63.49M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 73.03M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 58.00M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 22.46M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.75M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 4.63M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 119.93M | n/a | n/a | n/a |
About iBio Inc
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is iBio Inc's market cap?
iBio Inc's market capitalization is USD 73.03M.
What does iBio Inc do?
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.